World's Best Scientists 2026 revealed!
Jean-Michel Molina

Jean-Michel Molina

D-Index & Metrics

Medicine

D-Index
98
Citations
41712
World Ranking
8836
National Ranking
267

Jean-Michel Molina publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jean-Michel Molina sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 618 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jean-Michel Molina D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jean-Michel Molina sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jean-Michel Molina is affiliated with Université Paris Cité in France. Their research primarily focuses on infectious diseases and HIV/AIDS, with substantial contributions to the fields of medicine, immunology, and microbiology.

The scientist's recent publications include:

  • No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection, 2020, Médecine et Maladies Infectieuses
  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults, 2022, JAMA
  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults, 2020, JAMA
  • Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial, 2020, The Lancet
  • Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection, 2022, New England Journal of Medicine

Jean-Michel Molina frequently collaborates with several researchers, including:

  • Constance Delaugerre
  • Christine Katlama
  • Nathalie De Castro
  • Lambert Assoumou
  • Laurence Meyer

Their work has appeared predominantly in the following venues:

  • Clinical Infectious Diseases
  • Open Forum Infectious Diseases
  • Médecine et Maladies Infectieuses Formation
  • AIDS
  • Journal of Antimicrobial Chemotherapy

The scientist's research fields include:

  • Medicine
  • Immunology and Microbiology

Within these broader fields, subfields of study are:

  • Infectious Diseases
  • Epidemiology
  • Virology
  • Emergency Medicine
  • Surgery

Core research topics include:

  • HIV/AIDS Research and Interventions
  • HIV Research and Treatment
  • HIV/AIDS drug development and treatment
  • HIV-related health complications and treatments
  • HIV, Drug Use, Sexual Risk
  • Pneumocystis jirovecii pneumonia detection and treatment
  • COVID-19 Clinical Research Studies

Best Publications

  • Initiation of antiretroviral therapy in early asymptomatic HIV infection

    Sean Emery;Shweta Sharma;Gerd Fätkenheuer;Josep M. Llibre

  • HLA-B*5701 Screening for Hypersensitivity to Abacavir

    Simon Mallal;Elizabeth Phillips;Giampiero Carosi;Jean-Michel Molina

  • On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

    Abstr Act;C. Capitant;B. Spire;G. Pialoux

  • Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

    Paul E Sax;David Wohl;Michael T Yin;Frank Post

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel

    Michael S. Saag;Constance A. Benson;Rajesh T. Gandhi;Jennifer F. Hoy

  • Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

    Jean-Michel Molina;Jaime Andrade-Villanueva;Juan Echevarria;Ploenchan Chetchotisakd

  • Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

    Bonaventura Clotet;Nicholas Bellos;Jean Michel Molina;David Cooper

  • Hematopoietic growth factors. Biology and clinical applications.

    J E Groopman;J M Molina;D T Scadden

  • Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial

    Jean Michel Molina;Pedro Cahn;Beatriz Grinsztejn;Adriano Lazzarin

  • Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study

    Jean-Michel Molina;Jean-Michel Molina;Isabelle Charreau;Bruno Spire;Laurent Cotte

  • Tenofovir-Related Nephrotoxicity in Human Immunodeficiency Virus-Infected Patients: Three Cases of Renal Failure, Fanconi Syndrome, and Nephrogenic Diabetes Insipidus

    Alexandre Karras;Matthieu Lafaurie;André Furco;Anne Bourgarit

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel.

    Michael S. Saag;Rajesh T. Gandhi;Jennifer F. Hoy;Raphael J. Landovitz

  • Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

    Edwin DeJesus;Jürgen K. Rockstroh;Keith Henry;Jean Michel Molina

  • Enhanced T cell recovery in HIV-1–infected adults through IL-7 treatment

    Yves Levy;Christine Lacabaratz;Laurence Weiss;Jean-Paul Viard

  • Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

    Kenneth H Mayer;Kenneth H Mayer;Jean-Michel Molina;Melanie A Thompson;Peter L Anderson

  • Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.

    Jean-Michel Molina;Isabelle Charreau;Christian Chidiac;Gilles Pialoux

  • Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

    Antonella Castagna;Franco Maggiolo;Giovanni Penco;David Wright

  • Prognostic Factors and Outcome of Human Herpesvirus 8–Associated Primary Effusion Lymphoma in Patients With AIDS

    Emmanuelle Boulanger;Laurence Gérard;Jean Gabarre;Jean-Michel Molina

  • Fumagillin Treatment of Intestinal Microsporidiosis

    Jean-Michel Molina;Muriel Tourneur;Claudine Sarfati;Sylvie Chevret

  • Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.

    Jean-Michel Molina;Jaime Andrade-Villanueva;Juan Echevarria;Ploenchan Chetchotisakd

Frequent Co-Authors

Constance Delaugerre
Constance Delaugerre Université Paris Cité
Gilles Pialoux
Gilles Pialoux Tenon Hospital
Francis Derouin
Francis Derouin Université Paris Cité
Geneviève Chêne
Geneviève Chêne University of Bordeaux
Laurence Meyer
Laurence Meyer University of Paris-Saclay
Christine Katlama
Christine Katlama Sorbonne University
Edwin DeJesus
Edwin DeJesus Hanover University of Applied Sciences and Arts
Philippe Morlat
Philippe Morlat University of Bordeaux
Chloe Orkin
Chloe Orkin Queen Mary University of London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to diverse online degrees and allied health pathways. Students interested in holistic care often choose an online degree in nutrition. This program blends science and health, preparing graduates for roles in dietetics, wellness, and public health.

For those seeking healthcare leadership positions, a cahme accredited online mha program ensures training in administration and management from a reputable source. Nurses looking to advance can benefit from online rn to bsn programs without clinical requirements, offering flexibility for busy professionals.

For advanced nursing leaders, the shortest dnp program online helps experienced nurses reach the highest level of practice efficiently. Each pathway is designed to be flexible, with accredited options, making them accessible even for those balancing work and study.

Best Scientists Citing Jean-Michel Molina

Trending Scientists